Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Delayed Start, Double Blind, Parallel Group, Placebo Controlled, Multicenter Study of Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease

NCT05267535 is registered in ClinicalTrials.gov with Neurim Pharmaceuticals Ltd. as lead sponsor.

NCT NCT05267535
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05267535 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Delayed Start, Double Blind, Parallel Group, Placebo Controlled, Multicenter Study of Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease
Lead sponsor
Neurim Pharmaceuticals Ltd.
Phase
Phase 2/3
Overall status
Terminated
Start date
June 15, 2022
Completion date
December 12, 2024
Enrollment
216 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease